Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesYpsomed Holding AG

Ypsomed Holding AG

PortfolioPortfolio WatchlistWatchlist
Company price
388.6 GBX 0.40 ( 0.10%)
Last update at 2026-10-27T16:02:00Z
VOLUME
62
Market Cap
3516.27M
P/E
1.54

Momentum Score

…

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
386.40
Low
388.80
High
52 Week Price Range
263.50
Low
440.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Ypsomed Holding AG is a Swiss medical-device company that develops and manufactures injection and infusion systems and associated digital therapy-management tools for diabetes and other chronic conditions. Long-term growth may be supported by rising diabetes prevalence, increasing adoption of insulin pumps and connected care, and recurring revenue from consumables and outsourced device manufacturing for pharmaceutical partners. Investors may find the company attractive for its integrated device-plus-software positioning and recurring-revenue business model.
Key risks include regulatory and reimbursement hurdles, intense competition from larger medtech players, product safety or technological obsolescence, dependence on a small number of major customers, and supply-chain or manufacturing disruptions.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
388.20
Dividend Yield
0.78%
Revenue TTM
787.55M
Revenue Per Share
57.71
Gross Profit TTM
309.46M
Debt / Equity
0.39
ROE
27.15%
Net Debt
230.50M
ROCE
13.30%
Diluted EPS TTM
1.83

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax 104.31M 81.87M 56.64M 25.54M 6.11M
Net income 87.50M 78.37M 51.27M 23.11M 5.81M
Selling general administrative 35.80M 29.11M 26.22M 23.03M 21.09M
Selling and marketing expenses 89.74M 78.88M 77.07M 66.39M 72.96M
Gross profit 292.07M 189.05M 140.59M 113.82M 94.83M
Ebit 110.96M 86.69M 43.20M 28.58M 9.17M
Ebitda 190.90M 161.56M 87.55M 68.88M 43.26M
Depreciation and amortization 79.94M 74.87M 44.35M 40.30M 34.09M
Operating income 112.85M 86.22M 43.20M 28.58M 9.17M
Other operating expenses 636.01M 462.24M 438.76M 437.34M 396.10M
Interest expense 6.64M 5.04M - 0.00M 0.00M
Tax provision - - - - 0.30M
Interest income - - - - 3.10M
Income tax expense 16.81M 3.51M 5.36M 2.44M 0.30M
Total revenue 748.87M 548.46M 497.46M 464.84M 403.66M
Total operating expenses 179.21M 102.83M 81.89M 86.32M 87.27M
Cost of revenue 456.80M 359.40M 356.87M 351.02M 308.83M
Total other income expense net -8.54M -4.35M 13.44M -3.04M -3.06M
Net income applicable to common shares - - - 23.11M 5.81M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 1330.34M 1101.39M 861.88M 756.91M 717.68M
Intangible assets 310.42M 281.58M 30.50M 34.24M 35.87M
Other current assets 101.22M 47.61M 32.06M 21.26M 26.71M
Total liab 650.66M 483.66M 299.55M 364.37M 322.30M
Total stockholder equity 679.68M 617.73M 562.33M 392.54M 395.38M
Deferred long term liab - - 201.24M 156.54M 124.86M
Other current liab 170.82M 147.13M 239.37M 219.95M 237.82M
Common stock 193.14M 193.14M 193.14M 178.99M 178.99M
Retained earnings 645.93M 572.08M 502.59M 455.41M 439.63M
Other liab - - - 17.03M 17.42M
Other assets 0.00M - 232.74M 190.29M 159.63M
Cash 36.49M 74.02M 25.22M 17.04M 19.32M
Total current liabilities 496.19M 440.22M 258.99M 237.34M 272.38M
Current deferred revenue - 74.81M - - -
Net debt 230.50M 181.98M -25.22M -17.04M -19.32M
Short term debt 267.00M 181.19M - - 182.50M
Short long term debt total 267.00M 256.00M - - 32.50M
Other stockholder equity -159.39M -147.49M -133.40M -241.86M -223.24M
Property plant equipment - - - 336.15M 334.38M
Total current assets 426.95M 337.94M 208.33M 193.58M 185.14M
Net tangible assets - - 531.83M 358.30M 359.52M
Short term investments - 0.57M - - 3.09M
Net receivables 203.48M 141.03M 93.34M 86.99M 72.66M
Long term debt - - - - 32.50M
Inventory 85.75M 75.29M 57.70M 68.30M 63.36M
Accounts payable 37.37M 30.88M 19.62M 17.39M 34.55M
Accumulated other comprehensive income - -147.49M - - -
Treasury stock - - - - -0.96M
Non currrent assets other 14.25M 10.68M -420.81M -373.03M -372.91M
Non current assets total 903.39M 763.45M 420.81M 373.03M 372.91M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments - - - 2.84M 6.38M
Change to liabilities - - 0.00M 2.18M 1.61M
Total cashflows from investing activities -267.27M -195.07M - -125.70M -106.91M
Net borrowings - - - 52.00M 22.00M
Total cash from financing activities 82.25M 81.07M 1.26M 38.12M 26.67M
Change to operating activities - - - 12.75M -10.13M
Net income 87.50M 78.37M 51.27M 23.11M 5.81M
Change in cash -37.52M 48.79M 8.19M -2.28M 5.93M
Begin period cash flow 74.02M 25.22M 17.04M 19.32M 13.39M
End period cash flow 36.49M 74.02M 25.22M 17.04M 19.32M
Total cash from operating activities 148.20M 163.22M 129.53M 85.71M 85.83M
Depreciation 79.94M 74.87M 44.35M 40.30M 34.09M
Other cashflows from investing activities -69.90M -78.70M - - 19.67M
Dividends paid 27.30M 17.75M 8.19M 14.67M 2.52M
Change to inventory -16.04M -17.89M -4.30M -5.92M -6.30M
Change to account receivables -84.48M -33.30M -18.33M -16.43M 5.03M
Sale purchase of stock -2.53M -1.32M -1.76M -0.26M 6.14M
Other cashflows from financing activities -0.00M 0.00M 36.21M 53.05M 29.19M
Change to netincome - - - 1.94M 33.79M
Capital expenditures 277.15M 195.31M 98.88M 51.59M 59.18M
Change in working capital -66.24M -46.10M -22.63M -22.35M -1.27M
Other non cash items 46.99M 56.09M 56.54M 44.65M 47.20M
Free cash flow -128.95M -32.09M 30.65M 34.11M 26.64M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0QLQ
Ypsomed Holding AG		 0.40
0.10%		 388.60 1.54 - 4.46 -
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Ypsomed Holding AG

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.

Brunnmattstrasse 6, Burgdorf, Switzerland, 3401

41 34 424 41 11

https://www.ypsomed.com

2000

Name Title Year Born
Ms. Ulrike Bauer Chief Bus. Officer 1969
Mr. Simon Michel CEO & Member of the Board 1977
Mr. Niklaus Ramseier Chief Financial Officer 1963
Mr. Frank Mengis COO & Sr. VP of Operations 1964
Thomas Kutt Head of Investor Relations NA
Dr. Beat Maurer Chief Legal Officer 1958
Mr. Michael Zaugg Chief Corp. Officer 1972
Mr. Sebastien Delarive Chief Bus. Officer 1970
Mr. Samuel Kunzli Chief Financial Officer 1984
Mr. Frank Mengis Chief Operating Officer 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…